Clinical trials: Elevated PSA
Prostate Cancer
Radium 223 Following Intermittent ADT
This is a multicentre, phase II, randomized, open label study to evaluate the efficacy and safety of monthly Radium 223 in prolonging the off treatment interval of men with localized prostate cancer receiving intermittent…
- Trial name
- RAND (NCT02656563)
- Testing
- Radium 223 Dichloride (Xofigo®)
- Where
- Canada
- Sponsor
- Canadian Urology Research Consortium
Prostate Cancer
Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer
RATIONALE: Calcitriol, a form of vitamin D, may be able to prevent or slow the growth of prostate cancer cells. PURPOSE: Phase II trial to study the effectiveness of calcitriol in treating patients who have a rising PSA level…
- Trial name
- NCT00004043
- Testing
- calcitriol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
ExosomeDx in MRI-negative Men With High PSA
Magnetic resonance imaging (MRI) has become the current standard of care in risk stratifying men with an elevated Prostate-specific antigen (PSA) to determine who needs to undergo prostate biopsy, which is invasive and carries a…
- Trial name
- NCT06966089
- Testing
- Urinary ExoDx test, Transrectal ultrasound-guided prostate biopsy, Transperineal 12-core prostate biopsy
- Where
- 6 sites in United States
- Volunteers
- 425 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of localized prostate cancer.
- Trial name
- NCT00045123
- Testing
- tarenflurbil, adjuvant therapy
- Where
- 58 sites in United States
- Sponsor
- Myrexis Inc.